Latest Market Impact News

Australian Pacific Coal Limited’s Dartbrook Mine has entered receivership, with the company now assuming no residual value in the asset. Despite this, AQC maintains solvency and continues to explore its options amid ongoing financial challenges.

Tungsten Mining has successfully raised $53 million through a heavily oversubscribed placement, positioning itself to advance its critical tungsten projects amid rising commodity prices.

Desert Metals Limited has completed the second tranche of its placement, raising a total of $1.25 million through new shares and options issued to investors and its lead manager.

Clover Corporation has initiated an on-market acquisition of up to 3.26 million shares to satisfy future employee share plan vesting, aiming to reduce shareholder dilution from new share issuances.

AMCIL Limited has announced a fresh on-market buy-back program targeting up to 24 million shares, aiming to enhance capital management without requiring shareholder approval.

RPMGlobal has secured a crucial Foreign Investment Review Board approval for its proposed acquisition by Caterpillar, marking a significant step forward in the takeover process.

The Australian Competition and Consumer Commission has advanced its review of Ampol’s acquisition of EG Australia to a more detailed Phase 2 assessment, signalling potential competition concerns. Ampol remains optimistic about completing the deal by mid-2026 despite the regulatory scrutiny.

The ACCC has referred Ampol’s acquisition of EG Australia to a detailed Phase 2 review, citing significant competition concerns in multiple Australian fuel markets. Ampol’s proposed divestments have so far failed to satisfy the regulator.

Australian Strategic Materials and Energy Fuels are set to discuss their proposed acquisition in a joint webcast, offering investors a closer look at this strategic move.

Finbar Group has achieved over 70% presales for its Palmyra West Apartments project, signalling strong market demand ahead of construction starting in March 2026.

VBX Limited reports a significant 51% increase in the Measured and Indicated Mineral Resource Estimate for its Wuudagu B and C plateaus, setting the stage for a longer mine life and enhanced project economics.

Telix Pharmaceuticals has achieved a key milestone with China’s NMPA accepting its New Drug Application for Illuccix, a prostate cancer imaging agent backed by strong Phase 3 data. This paves the way for Telix to enter a rapidly growing Chinese market alongside its global approvals.